<DOC>
	<DOCNO>NCT02652494</DOCNO>
	<brief_summary>This multicenter , prospective , non-interventional , observational single arm study . Two-hundred patient recruit Netherlands one year period . In case , decision treat patient apremilast make prior decision enter subject study . Treatment accord routine clinical practice base recommendation per SPC apremilast ( Otezla® ) . Recruitment continue 200 patient enter study . Each patient follow 12 month .</brief_summary>
	<brief_title>Observational Study Apremilast Patients With Psoriasis The Netherlands</brief_title>
	<detailed_description>Baseline Demographics , disease characteristic medication history prior start treatment apremilast collect . Patients ask complete baseline Dermatology Life Quality Index ( DLQI ) , Short Form 36 ( SF36 ) , EuroQol-5 dimension ( EQ5D ) , Treatment Satisfaction Questionnaire Medication ( TSQM ) Work Productivity Activity Impairment ( WPAI ) questionnaires . Photographs finger nail take . Follow-up visit Follow-up assessment take place regularly schedule outpatient visit 6 12 month ( +/- 1 month ) initiation apremilast . - Skin-specific disease measure ( Psoriasis Activity Severity Index ( PASI ) , ( static ) Physician Global Assessment ( sPGA ) , Body Surface Area ( BSA ) ) - Patients ask complete follow questionnaire : - DLQI - TSQM - EQ5D - SF36- Itch Visual Analog Scale ( VAS ) End treatment Upon discontinuation treatment apremilast , date , dose reason discontinuation document . AE monitor All patient monitor adverse event throughout study . From time patient signing informed consent treatment apremilast permanently abrogate , non-serious adverse event consider related apremilast Serious Adverse Events ( SAEs ) regardless causality report .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients ≥ 18 year age understand voluntarily sign informed consent form . Patients start treatment psoriasis apremilast clinical practice . Refusal participate study . Women pregnant breastfeeding . Hypersensitivity active substance excipients . Prior exposure apremilast Psoriatic arthritis treat rheumatologist previous year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Observational</keyword>
	<keyword>Apremilast</keyword>
	<keyword>APRIL</keyword>
	<keyword>Non-Interventional</keyword>
	<keyword>The Netherlands</keyword>
</DOC>